SCHEMBL623465

SCHEMBL623465

N#Cc1cccc(C(=Cc2ccccc2)C(N)=O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.49
GSK3B P49841 2/20 0.47
AKR1C1 Q04828 1/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
KMT2A Q03164 2/20 0.46
PKM P14618 1/20 0.46
ATM Q13315 1/20 0.46
P4HB P07237 6/20 0.45
FBP1 P09467 2/20 0.45
GRIN2D O15399 2/20 0.43
GRIN3B O60391 2/20 0.43
GRIN1 Q05586 2/20 0.43
GRIN2A Q12879 2/20 0.43
GRIN2B Q13224 2/20 0.43
GRIN2C Q14957 2/20 0.43
GRIN3A Q8TCU5 2/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623464 1.00 MCL1 (0.49) MCL1GSK3BAKR1C1ALDH1A1KDM4E
SCHEMBL622906 0.88 AKR1C1 (0.62) GSK3BAKR1C1ALDH1A1KDM4EKMT2A
SCHEMBL622907 0.88 AKR1C1 (0.62) GSK3BAKR1C1ALDH1A1KDM4EKMT2A
SCHEMBL23593943 0.79 AKR1C1 (0.70) MCL1AKR1C1ALDH1A1KDM4EKMT2A
SCHEMBL2836206 0.79 AKR1C1 (0.70) MCL1AKR1C1ALDH1A1KDM4EKMT2A
SCHEMBL6689798 0.79 AKR1C1 (0.70) MCL1AKR1C1ALDH1A1KDM4EKMT2A
SCHEMBL10284967 0.79 PBRM1 (0.54) MCL1AKR1C1ALDH1A1KDM4EKMT2A
SCHEMBL2041048 0.74 GSK3B (0.61) GSK3BMAPTL3MBTL1POLBVNN1
SCHEMBL171168 0.74 GSK3B (0.61) GSK3BMAPTL3MBTL1POLBVNN1
Phosphoric Acid SCHEMBL3676597 0.73 AKR1C1 (0.61) MCL1AKR1C1ALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238619-B2 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-19 US disclosed
US-8877794-B2 Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBOTT LABORATORIES (US) 2014-11-04 US disclosed
US-20140256701-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2014-09-11 US disclosed
EP-2603487-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott GmbH & Co. KG (DE) 2013-06-19 EP disclosed
US-20120077796-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT LABORATORIES (US) 2012-03-29 US disclosed
WO-2012020130-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO. KG (DE) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256701-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY KCNT1, CEPT1, PIGT MCL1 3193/4885GSK3B 2954/4885AKR1C1 1739/4885
US-20120077796-A1 PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY KCNT1, CEPT1, PIGT MCL1 3193/4885GSK3B 2954/4885AKR1C1 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.